JTS-653

JTS-653 is a highly potent and selective transient receptor potential vanilloid 1 (TRPV1) antagonist in vitro and in vivo. JTS-653 attenuates chronic pain refractory to non-steroidal anti-inflammatory agents[1].

Product Specifications

CAS Number

[942614-99-5]

UNSPSC

12352005

Target

TRP Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/jts-653.html

Solubility

10 mM in DMSO

Smiles

OC[C@@H]1N(C(N=C2)=CC=C2C)C3=CC=CC(C(NC(C=C4)=CN=C4OCC(F)(F)F)=O)=C3OC1

Molecular Formula

C23H21F3N4O4

Molecular Weight

474.43

References & Citations

[1]Yoshihiro Kitagawa, et al. Pharmacological characterization of (3S) -3- (hydroxymethyl) -4- (5-methylpyridin-2-yl) -N-[6- (2,2,2-trifluoroethoxy) pyridin-3-yl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide (JTS-653), a novel transient receptor potential vanilloid 1 antagonist. J Pharmacol Exp Ther. 2012 Aug;342 (2) :520-8.|[2]Yoshihiro Kitagawa, et al. Orally administered selective TRPV1 antagonist, JTS-653, attenuates chronic pain refractory to non-steroidal anti-inflammatory drugs in rats and mice including post-herpetic pain. J Pharmacol Sci. 2013;122 (2) :128-37.